H.C. Wainwright analyst Joseph Pantginis says Leerink this morning downgraded Compass Therapeutics (CMPX) saying the company’s biliary ...

Three of the total 103 research projects on the list involve researchers at KI: AI for early detection and prognosis of ...

In 2023, Sydney Towle, then 23, developed a bump on her abdomen that she could feel. When she exercised, she experienced a ...

Women have an increased global burden of gallbladder and biliary tract cancer (GBTC) compared with men, according to a study in the Journal of Gastroenterology and Hepatology.

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first ...

Graves disease and cancer were associated with each other, as Graves disease diagnosis was linked to increased risks for ovarian and prostate cancers.

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

Known as a 'silent' cancer, it often doesn't present symptoms until it has progressed, but there are some signs you should ...

PDUFA date for potential approval of Zanidatamab is set for Nov 29, developed in collaboration with Jazz Pharmaceuticals and BeiGene. Find out why ZYME stock is a Buy.

Not much is known about how D-mannose works, but many experts believe it inhibits the ability of certain infectious bacteria to adhere to the cells of your urinary tract, making it easier for them ...

Zymeworks (ZYME) stock fell as Wells Fargo downgrades company, citing potential FDA nod for cancer therapy zanidatamab is already priced in its shares. Read more here.